Product Description
(Sourced from: https://investors.abbvie.com/static-files/6d04e489-98d6-47f5-b310-bfaa0704f3b3)
Mechanisms of Action: IL13 Inhibitor, IL31 Inhibitor
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: AbbVie
Company Location: Eastern America
Company Founding Year: 2013
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07673120 |
M26-216 | P1 |
Recruiting |
Healthy Volunteers |
2028-02-01 |
12% |
2026-06-30 |
Primary Endpoints|Treatments |
Recent News Events
Date |
Type |
Title |
|---|